Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma2026-07-14T15:51:46-07:00July 8th, 2026|Read more
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia2026-07-09T17:06:05-07:00June 3rd, 2026|Read more
NGS-based MRD monitoring in mature B-cell and plasma cell malignancies2026-07-09T17:08:21-07:00May 28th, 2026|Read more
T-cell receptor gamma (TRG) diversity predicts peripheral blood involvement in primary cutaneous T-cell lymphoma2026-07-09T17:12:44-07:00March 5th, 2026|Read more
Ultrasensitive next-generation sequencing-based clonality assay for disease monitoring in B-cell acute lymphoblastic leukaemia2026-07-07T11:50:22-07:00February 20th, 2026|Read more
Invivoscribe Announces the PrepQuantTM System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows2026-07-07T11:48:53-07:00April 15th, 2026|Read more
Invivoscribe Expands IVDR Portfolio with IdentiClone Dx IGH Assay Certification2026-03-25T23:07:06-07:00March 25th, 2026|Read more
Invivoscribe Launches LeukoStratKMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide2026-02-05T14:09:13-08:00February 4th, 2026|Read more
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial2026-03-09T18:04:28-07:00July 7th, 2025|Read more
LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials2026-03-09T18:40:09-07:00June 17th, 2025|Read more
115th The Annual meeting of the Japanese Society of Pathology Apr 16 – 18, 2026Â Sapporo, Japan Attending
2nd EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms Apr 30–May 2, 2026 Ljubljana, Slovenia Attending Visit Conference Website